[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto Nacional de Enfermedades Respiratorias\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100589810","glycine-and-magnesiumthiamine-for-the-treatment-of-primary-ciliary-dyskinesia-100589810",false,"NCT06959251","Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia","A Randomized, Placebo-controlled Clinical Trial Evaluating the Efficacy and Safety of Glycine and Magnesium+Thiamine Supplements, Alone or Combined, Administered for 6 Months to Patients With Primary Ciliary Dyskinesia","Inclusion Criteria:\n\n1. Any sex.\n2. Age of 5 years or more.\n3. Diagnosis of primary ciliary dyskinesia (PCD) established according to international recommendations (Shapiro et al. Am J Respir Crit Care Med 2018;197(12):e24-e39, and Shapiro et al. Ped Pulmonol 2016;51:115-132).\n4. Without respiratory exacerbations of PCD in the previous 30 days.\n5. Without acute respiratory infection in the previous 30 days.\n6. Informed consent letter signed by the patient (if the patient's age is 18 years or more).\n7. Informed consent letter signed by the legal guardian, and assent letter signed by the patient (if the patient's age is \\\u003C18 years).\n\nExclusion Criteria:\n\n1\\. Participation in other research protocol involving therapeutic measures.\n\nElimination Criteria:\n\n1\\. None.","ALL","5 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","* Patients with primary ciliary dyskinesia (PCD) have trouble with clearing their bronchi from mucus, which in the long-term may produce severe damage to the lungs. Currently, there is no specific treatment for PCD beyond supportive measures such as airway hydration and postural drainage.\n* Glycine is an amino acid with anti-inflammatory properties that proved to be beneficial in another disease with problematic airway clearance, cystic fibrosis.\n* Magnesium participates in many crucial chemical reactions, including some that might favor fluidification and mobilization of mucus. Thiamine (vitamin B1) co-participates with magnesium in some mitochondrial enzymatic reactions occurring in the citric acid cycle.\n* Thus, oral supplements of glycine and magnesium+thiamine might improve symptoms and lung function of patients with PCD, and these effects may even be better if these supplements are combined.\n* In this study, in addition to their usual care, patients with PCD will receive for 6 months one of the following treatments: 1) an oral supplement of 0.5 g\u002Fkg\u002Fday glycine, 2) an oral supplement of up to 400 mg\u002Fday elementary magnesium plus up to 10 mg\u002Fday thiamine, according to the subject's age, 3) glycine plus magnesium+thiamine supplements, as described, or 4) a placebo, which is an inert substance. All treatments will be administered as a whitish powder contained in similar bottles.\n* The investigators will evaluate whether glycine and\u002For magnesium+thiamine reduce exacerbations of the disease, improve pulmonary function and quality of life, and reduce some pro-inflammatory compounds measured in saliva.",[26],"Primary Ciliary Dyskinesia",[28,29,30,31,32,33],"Primary ciliary dyskinesia","Glycine","Magnesium","Lung function","thiamine","benfotiamine","RECRUITING","2025-11-20",{"date":37,"type":38},"2025-11-25","ACTUAL",{"date":40,"type":38},"2025-10-02",{"date":42,"type":20},"2028-03",{"name":44,"class":45},"Instituto Nacional de Enfermedades Respiratorias","OTHER_GOV",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100569213","caspofungin-for-pneumocystis-pneumonia-in-plwhiv-100569213","NCT06691321","Caspofungin for Pneumocystis Pneumonia in PLWHIV.","Efficacy of Caspofungin for Pneumocystis Jirovecii Pneumonia in People Living With HIV\u002FAIDS.","Inclusion Criteria:\n\n* Diagnosis of probable or proven PCP, according to its diagnostic classification (refer to classification at the end of this section).\n* Have clinical laboratory and virological diagnostic laboratory studies at the time of admission.\n\n  * Classification criteria for Pneumonia by P. jirovecii according to Robert-Gangneux et al.:\n\nProven: Confirmation by pathology or microbiology. Possible: Presence of three out of four clinical or radiological criteria. Probable: Presence of one clinical or radiological criterion without another identified microorganism.\n\nExclusion Criteria:\n\n* With a treatment switch to caspofungin after day 7 of treatment initiation (applies only to group B).\n* Patients who have developed an additional opportunistic lung infection during their hospitalization, other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia.","18 Years","60 Years",{"count":19,"type":20},"OBSERVATIONAL","Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV\u002FAIDS, often severe and potentially fatal. While trimethoprim\u002Fsulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.",[60,61],"HIV-1-infection","Pneumocystis Pneumonia",[63,64,65],"Pneumocystis jirovecii pneumonia","Echinocandins","Caspofungin","2024-11-15",{"date":68,"type":38},"2024-11-19",{"date":70,"type":38},"2023-08-01",{"date":72,"type":20},"2025-09-01",{"name":44,"class":45},""]